Ocera Therapeutics (OCRX) Reports Q4 Loss of $0.22/Share

Ocera Therapeutics (NASDAQ: OCRX) reported Q4 EPS of ($0.22), versus ($0.34) reported last year.

Financial Guidance

Ocera anticipates it will have sufficient cash to fund operations into the second quarter of 2018 based on its current operating plan and re-prioritization of certain development activities

For earnings history and earnings-related data on Ocera Therapeutics (OCRX) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c
• XP Inc. (XP) Tops Q2 EPS by 8c